Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

immatics Appoints Peter Chambré as Chairman

Published: Monday, November 12, 2012
Last Updated: Monday, November 12, 2012
Bookmark and Share
Peter Chambré will replace Thomas Widmann.

immatics biotechnologies GmbH has announced the appointment of Peter Chambré as Chairman of the Board with immediate effect.

Peter Chambré has had extensive senior management experience in the biopharmaceutical sector and now holds several Chairman positions in the life sciences industry.

He will replace Thomas Widmann, who has been Chairman of the Company since 2004.

Peter Chambré was CEO of Cambridge Antibody Technology (CAT), from 2002 until its acquisition by AstraZeneca in 2006.

Before joining CAT, Peter Chambré was Chief Operating Officer of Celera Genomics Group and, previously, CEO of Bespak plc, a drug delivery company.

Following these major executive roles in the sector, Peter Chambré has held several Chairman and Non-executive Director positions.

From 2008-2010, he was Chairman of ApaTech, a specialist in orthobiologic bone graft technologies, which was acquired by Baxter Inc. in March 2010, and from 2006-2012, Non-executive Director of BTG plc.

Peter Chambré currently holds Chairman and Non-executive Board roles with a number of companies.

Paul Higham, CEO of immatics, said: “I am delighted to welcome Peter as our new Chairman. We are approaching a crucial period at immatics, and Peter’s experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximize returns to our investors.”

Peter Chambré said: “immatics’ vaccines, based on the Company’s highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials. With IMA901, immatics’ lead multi-peptide based vaccine now in phase 3 development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company. On behalf of immatics, I would like to express my thanks to Thomas Widmann for his very significant contribution to the development of the Company over the past 8 years. I very much look forward to working with the Board and management, as immatics aims to improve outcomes for cancer patients and create value for all its stakeholders.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Immatics and MD Anderson Announce Launch of Immatics US, Inc.
Launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.
Wednesday, August 26, 2015
New EU-funded Consortium to Develop Fully Personalized Cancer Vaccines
Multinational clinical trial treating glioblastoma patients with fully personalized therapeutic vaccines planned to start in 2014.
Friday, July 05, 2013
immatics’ Renal Cancer Vaccine IMA901 Completes Phase 3 Patient Recruitment
Drug is granted US orphan drug designation by the FDA.
Thursday, November 08, 2012
immatics Announces Publication of IMA901 Cancer Vaccine Data in Nature Medicine
Paper highlights clinical and immunological activity of IMA901 in renal cell carcinoma (RCC).
Thursday, August 16, 2012
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
New Imaging Technique in Alzheimer’s Disease
Study confirms new imaging technique corresponds a higher degree of actual brain changes.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!